The good news continues as BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma.
At the 5th Annual Cell Engager Summit (April 25 – 27) we are bringing together the top minds in multi specific T cell engagers. With over 24+ KOLs from industry and academia, this is not one to miss.
- Nicholas Sabbarth, Head of Biotherapeutics Discovery & Cancer Immunology at Boehringer Ingelheim – guiding us through the discovery concepts that brought BI to their novel pHLA T Cell engager.
- Diego Ellerman, Principal Research Scientist at Genentech – discussing the tribulations that bispecifics have faced and what can be done to avoid these pitfalls in the future
- Erin Filbert, Director of Preclinical Research at Apexigen – focusing on the preclinical work going into their novel NK cell engager and how they’re accelerating their timeline IND enabling studies.
- Louise Koopman, Senior Scientist at Genmab – explaining their approach to breaking into the solid effectively for maximized therapeutic effect.
- Martin Siegemund, Senior Scientist of Early-Stage Project Leadership at Pieris Pharmaceuticals – exploring the novel costimulators that facilitate generation of multi specific protein formats addressing specific biological modalities.
View the full speaker faculty & their fantastic presentations here – including decisions makers from ICM Bioscience, Regeneron Pharmaceuticals, Link Immunotherapeutics, Amgen and many more.
Don’t forget to register your place by Friday, March 31 to save up to $500 on your ticket – learn more here: https://cell-engager-summit.com/take-part/register/